31 июл. 2024 г. · For the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, ...

CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the ...

6 апр. 2024 г. · CARVYKTI® is now approved in the U.S. for the second-line treatment of adult patients with relapsed or refractory myeloma who have received at ...

30 мар. 2022 г. · On February 28, 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for the treatment of adult patients with relapsed or ...

8 апр. 2024 г. · Carvykti is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line ...

7 апр. 2024 г. · This press release covers the FDA-approval of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with ...

8 апр. 2024 г. · FDA Approves CARVYKTI® and ABECMA for Early Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma · Historical Use of CAR T ...

28 февр. 2022 г. · CARVYKTI is a B cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of ...

15 мар. 2024 г. · CARVYKTI® received U.S. Food and Drug Administration approval in February 2022 for the treatment of adults with relapsed or refractory multiple ...

5 апр. 2024 г. · Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for ...